The hallmarks of successful anticancer immunotherapy

Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and currently available immunotherapeutic agents are expensive and generally associated with considerable toxicity, calling for the identification...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Science translational medicine Ročník 10; číslo 459
Hlavní autori: Galluzzi, Lorenzo, Chan, Timothy A, Kroemer, Guido, Wolchok, Jedd D, López-Soto, Alejandro
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 19.09.2018
ISSN:1946-6242, 1946-6242
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and currently available immunotherapeutic agents are expensive and generally associated with considerable toxicity, calling for the identification of robust predictive biomarkers. The overall genomic configuration of malignant cells, potentially favoring the emergence of immunogenic tumor neoantigens, as well as specific mutations that compromise the ability of the immune system to recognize or eradicate the disease have been associated with differential sensitivity to immunotherapy in preclinical and clinical settings. Along similar lines, the type, density, localization, and functional orientation of the immune infiltrate have a prominent impact on anticancer immunity, as do features of the tumor microenvironment linked to the vasculature and stroma, and systemic factors including the composition of the gut microbiota. On the basis of these considerations, we outline the hallmarks of successful anticancer immunotherapy.
AbstractList Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and currently available immunotherapeutic agents are expensive and generally associated with considerable toxicity, calling for the identification of robust predictive biomarkers. The overall genomic configuration of malignant cells, potentially favoring the emergence of immunogenic tumor neoantigens, as well as specific mutations that compromise the ability of the immune system to recognize or eradicate the disease have been associated with differential sensitivity to immunotherapy in preclinical and clinical settings. Along similar lines, the type, density, localization, and functional orientation of the immune infiltrate have a prominent impact on anticancer immunity, as do features of the tumor microenvironment linked to the vasculature and stroma, and systemic factors including the composition of the gut microbiota. On the basis of these considerations, we outline the hallmarks of successful anticancer immunotherapy.Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and currently available immunotherapeutic agents are expensive and generally associated with considerable toxicity, calling for the identification of robust predictive biomarkers. The overall genomic configuration of malignant cells, potentially favoring the emergence of immunogenic tumor neoantigens, as well as specific mutations that compromise the ability of the immune system to recognize or eradicate the disease have been associated with differential sensitivity to immunotherapy in preclinical and clinical settings. Along similar lines, the type, density, localization, and functional orientation of the immune infiltrate have a prominent impact on anticancer immunity, as do features of the tumor microenvironment linked to the vasculature and stroma, and systemic factors including the composition of the gut microbiota. On the basis of these considerations, we outline the hallmarks of successful anticancer immunotherapy.
Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and currently available immunotherapeutic agents are expensive and generally associated with considerable toxicity, calling for the identification of robust predictive biomarkers. The overall genomic configuration of malignant cells, potentially favoring the emergence of immunogenic tumor neoantigens, as well as specific mutations that compromise the ability of the immune system to recognize or eradicate the disease have been associated with differential sensitivity to immunotherapy in preclinical and clinical settings. Along similar lines, the type, density, localization, and functional orientation of the immune infiltrate have a prominent impact on anticancer immunity, as do features of the tumor microenvironment linked to the vasculature and stroma, and systemic factors including the composition of the gut microbiota. On the basis of these considerations, we outline the hallmarks of successful anticancer immunotherapy.
Author Wolchok, Jedd D
López-Soto, Alejandro
Chan, Timothy A
Galluzzi, Lorenzo
Kroemer, Guido
Author_xml – sequence: 1
  givenname: Lorenzo
  orcidid: 0000-0003-2257-8500
  surname: Galluzzi
  fullname: Galluzzi, Lorenzo
  email: deadoc@vodafone.it
  organization: Université Paris Descartes/Paris V, 75006 Paris, France
– sequence: 2
  givenname: Timothy A
  orcidid: 0000-0002-9265-0283
  surname: Chan
  fullname: Chan, Timothy A
  organization: Weill Cornell School of Medicine, New York, NY 10065, USA
– sequence: 3
  givenname: Guido
  orcidid: 0000-0002-9334-4405
  surname: Kroemer
  fullname: Kroemer, Guido
  organization: Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden
– sequence: 4
  givenname: Jedd D
  orcidid: 0000-0001-6718-2222
  surname: Wolchok
  fullname: Wolchok, Jedd D
  organization: Department of Medicine, Parker Institute and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
– sequence: 5
  givenname: Alejandro
  surname: López-Soto
  fullname: López-Soto, Alejandro
  email: lopezsalejandro@uniovi.es
  organization: Departamento de Biología Funcional, Área de Inmunología, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33006 Oviedo, Spain. lopezsalejandro@uniovi.es
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30232229$$D View this record in MEDLINE/PubMed
BookMark eNpNUEtLxDAYDLLiPvQfiPTopWteTZqjLL5gwct6Ll_TL7SapmvSHvbfW3AFLzPDMAzMrMkiDAEJuWV0yxhXD8l2Y4SQfI_NFmDUJdUXZMWMVLniki_-6SVZp_RJqSpFoa7IUlAuOOdmReShxawF73uIXykbXJYmazElN_kMwthZCBZj1vX9FIaxxQjH0zW5dOAT3px5Qz6enw6713z__vK2e9znVko95gaFqCkD6ZwxRtDCaaaa0gHMWDTWFHXdNKIwiLourJZWORSWWj37ytR8Q-5_e49x-J4wjVXfJYveQ8BhShVnolRCGE3n6N05OtXzIdUxdvOiU_W3lP8AE3hbuw
CitedBy_id crossref_primary_10_1038_s41577_025_01161_6
crossref_primary_10_1097_COC_0000000000000651
crossref_primary_10_1631_jzus_B2200528
crossref_primary_10_1002_adfm_202418090
crossref_primary_10_1038_s41598_023_41649_6
crossref_primary_10_3389_fimmu_2024_1365422
crossref_primary_10_1016_j_canrad_2019_07_152
crossref_primary_10_1016_j_cmet_2019_06_001
crossref_primary_10_1080_2162402X_2020_1806010
crossref_primary_10_1038_s41596_020_0299_3
crossref_primary_10_1038_s41590_022_01132_2
crossref_primary_10_1111_pcmr_12943
crossref_primary_10_1016_j_biopha_2020_110972
crossref_primary_10_1002_advs_202410011
crossref_primary_10_1373_clinchem_2019_303644
crossref_primary_10_15252_embj_2023114050
crossref_primary_10_1158_2326_6066_CIR_18_0903
crossref_primary_10_1136_jitc_2021_003190
crossref_primary_10_1016_j_cbi_2023_110342
crossref_primary_10_1080_2162402X_2018_1528815
crossref_primary_10_1111_imr_13271
crossref_primary_10_1158_0008_5472_CAN_23_1788
crossref_primary_10_3390_biology12030472
crossref_primary_10_1038_s41590_022_01373_1
crossref_primary_10_1158_2159_8290_CD_22_1220
crossref_primary_10_1039_D2NH00070A
crossref_primary_10_1016_j_semcancer_2022_05_015
crossref_primary_10_1208_s12248_020_00514_4
crossref_primary_10_1016_j_it_2021_09_002
crossref_primary_10_1002_iju5_12179
crossref_primary_10_1038_s41573_019_0043_2
crossref_primary_10_3390_cancers13236107
crossref_primary_10_1080_2162402X_2021_1944553
crossref_primary_10_1016_j_patol_2019_08_001
crossref_primary_10_1016_j_nut_2022_111637
crossref_primary_10_1002_adtp_202100098
crossref_primary_10_1038_s41467_022_29401_6
crossref_primary_10_3389_fimmu_2020_01295
crossref_primary_10_1007_s00262_022_03239_9
crossref_primary_10_1038_s41568_019_0209_6
crossref_primary_10_1073_pnas_2312929121
crossref_primary_10_2298_AOO241217003B
crossref_primary_10_1038_s41418_019_0290_0
crossref_primary_10_1016_j_bioelechem_2021_107795
crossref_primary_10_1038_s41420_021_00769_6
crossref_primary_10_1016_j_snb_2022_133086
crossref_primary_10_3389_fcell_2022_859958
crossref_primary_10_1016_j_cytogfr_2019_12_002
crossref_primary_10_1038_s41467_020_17644_0
crossref_primary_10_3389_fonc_2023_1132424
crossref_primary_10_1038_s41577_020_0300_y
crossref_primary_10_1002_adfm_202420278
crossref_primary_10_2147_IJN_S249174
crossref_primary_10_3389_fimmu_2019_02393
crossref_primary_10_3389_fimmu_2025_1568590
crossref_primary_10_1007_s00262_021_03071_7
crossref_primary_10_1007_s11033_023_08629_5
crossref_primary_10_1063_5_0041311
crossref_primary_10_1038_s41556_020_0568_y
crossref_primary_10_1093_intimm_dxaa010
crossref_primary_10_1371_journal_pbio_3000591
crossref_primary_10_3389_fneur_2022_977180
crossref_primary_10_1016_j_omto_2021_01_016
crossref_primary_10_1038_s44318_024_00217_y
crossref_primary_10_1136_jitc_2020_000979
crossref_primary_10_3390_cells14131010
crossref_primary_10_1002_ange_202006117
crossref_primary_10_3389_fimmu_2022_878457
crossref_primary_10_1016_j_tranon_2024_102175
crossref_primary_10_1007_s12539_025_00719_1
crossref_primary_10_3389_fonc_2021_683768
crossref_primary_10_3390_cancers12092418
crossref_primary_10_1016_j_biomaterials_2020_120648
crossref_primary_10_1038_s41422_020_0383_9
crossref_primary_10_1080_2162402X_2020_1721810
crossref_primary_10_1002_anbr_202300129
crossref_primary_10_1016_j_jconrel_2021_01_009
crossref_primary_10_1016_j_ccr_2024_216006
crossref_primary_10_1038_s41590_020_0751_0
crossref_primary_10_3390_cancers16162865
crossref_primary_10_36483_vanvetj_1654843
crossref_primary_10_1016_j_wneu_2023_08_020
crossref_primary_10_1016_j_nantod_2020_100987
crossref_primary_10_1080_2162402X_2023_2222560
crossref_primary_10_1155_2020_5024942
crossref_primary_10_1016_j_ymthe_2023_02_010
crossref_primary_10_1148_rg_2020200070
crossref_primary_10_1172_JCI145186
crossref_primary_10_1002_advs_202206669
crossref_primary_10_1016_j_omtm_2021_01_002
crossref_primary_10_3390_molecules25112692
crossref_primary_10_1002_adfm_202411103
crossref_primary_10_1111_1759_7714_14618
crossref_primary_10_3389_fmolb_2023_963639
crossref_primary_10_1016_j_ejca_2023_113347
crossref_primary_10_1016_j_ejphar_2020_173240
crossref_primary_10_1155_2024_3145695
crossref_primary_10_1016_j_bioactmat_2024_05_030
crossref_primary_10_1016_j_tcb_2018_08_005
crossref_primary_10_3389_fonc_2020_01027
crossref_primary_10_3390_pharmaceutics15041252
crossref_primary_10_1038_s41568_021_00366_w
crossref_primary_10_1016_j_molcel_2020_04_017
crossref_primary_10_1016_j_smim_2021_101481
crossref_primary_10_1007_s12274_021_3312_4
crossref_primary_10_1038_s41419_024_07283_4
crossref_primary_10_1016_S1470_2045_23_00451_5
crossref_primary_10_1038_s41565_022_01261_7
crossref_primary_10_1136_jitc_2022_006267
crossref_primary_10_1038_s41698_024_00749_w
crossref_primary_10_1007_s00262_021_03136_7
crossref_primary_10_1038_s41421_024_00666_z
crossref_primary_10_3389_fonc_2021_654388
crossref_primary_10_3892_ol_2021_12464
crossref_primary_10_1002_cbin_11655
crossref_primary_10_1016_S1470_2045_19_30171_8
crossref_primary_10_1016_j_ccell_2020_11_009
crossref_primary_10_3389_fphar_2022_1073713
crossref_primary_10_3390_jpm11090923
crossref_primary_10_1002_hed_25930
crossref_primary_10_1186_s40425_019_0506_3
crossref_primary_10_1002_bmm2_12067
crossref_primary_10_1038_s42003_023_04983_z
crossref_primary_10_1016_j_molimm_2020_09_013
crossref_primary_10_1111_cas_14161
crossref_primary_10_1038_s41573_022_00415_5
crossref_primary_10_1002_adfm_202100354
crossref_primary_10_1136_jitc_2020_001481
crossref_primary_10_1038_s41571_021_00579_w
crossref_primary_10_1002_adma_202300216
crossref_primary_10_1002_med_21765
crossref_primary_10_3390_immuno1030010
crossref_primary_10_3390_molecules29184405
crossref_primary_10_1007_s10528_023_10436_3
crossref_primary_10_1039_D5TB00044K
crossref_primary_10_1155_bmri_6180391
crossref_primary_10_1136_jitc_2021_002873
crossref_primary_10_3390_curroncol32050262
crossref_primary_10_3389_fimmu_2022_880959
crossref_primary_10_3390_cells12091305
crossref_primary_10_1038_s41467_022_31238_y
crossref_primary_10_3389_fimmu_2021_640369
crossref_primary_10_1016_j_isci_2025_112808
crossref_primary_10_1038_s41467_022_34041_x
crossref_primary_10_1016_j_bioactmat_2021_02_008
crossref_primary_10_3390_cancers12102940
crossref_primary_10_3389_fcell_2020_586757
crossref_primary_10_3390_ijms21207743
crossref_primary_10_1016_j_apsb_2019_07_004
crossref_primary_10_1186_s12967_023_04017_6
crossref_primary_10_3390_ph18050667
crossref_primary_10_1016_j_heliyon_2023_e19342
crossref_primary_10_1002_cam4_4705
crossref_primary_10_1016_j_ijpharm_2020_119498
crossref_primary_10_1038_s41420_022_01255_3
crossref_primary_10_1016_j_intimp_2023_110721
crossref_primary_10_1038_s41467_021_25057_w
crossref_primary_10_3390_pharmaceutics14051036
crossref_primary_10_1080_2162402X_2020_1777624
crossref_primary_10_1186_s12967_021_03002_1
crossref_primary_10_1172_JCI127471
crossref_primary_10_3390_cancers12061677
crossref_primary_10_1016_j_canlet_2021_12_017
crossref_primary_10_1038_s41467_020_18626_y
crossref_primary_10_3389_fimmu_2023_1061761
crossref_primary_10_3390_pharmaceutics14122710
crossref_primary_10_1093_bib_bbaf031
crossref_primary_10_1016_j_ejca_2025_115263
crossref_primary_10_1080_2162402X_2022_2052411
crossref_primary_10_1016_j_canlet_2025_217881
crossref_primary_10_3389_fonc_2021_591106
crossref_primary_10_1007_s12672_023_00836_7
crossref_primary_10_1016_j_canlet_2023_216193
crossref_primary_10_1172_JCI135528
crossref_primary_10_1186_s12964_024_01633_7
crossref_primary_10_1016_j_cell_2022_02_015
crossref_primary_10_1177_17588359251317144
crossref_primary_10_1002_adma_202002380
crossref_primary_10_1016_j_apsb_2025_08_020
crossref_primary_10_1186_s12885_021_08601_1
crossref_primary_10_23736_S1824_4785_20_03252_5
crossref_primary_10_3389_fimmu_2023_1170207
crossref_primary_10_15252_embj_2021108130
crossref_primary_10_1016_j_jconrel_2022_05_062
crossref_primary_10_1039_D4BM00083H
crossref_primary_10_1016_j_blre_2019_04_004
crossref_primary_10_1136_jitc_2020_001583
crossref_primary_10_1186_s40425_019_0698_6
crossref_primary_10_1038_s41388_022_02324_8
crossref_primary_10_1038_s41576_019_0166_7
crossref_primary_10_1186_s12943_021_01317_7
crossref_primary_10_1016_j_pharmthera_2019_04_004
crossref_primary_10_2147_IJN_S353330
crossref_primary_10_1016_j_biopha_2023_114824
crossref_primary_10_1136_jitc_2020_000802
crossref_primary_10_1007_s44178_023_00026_z
crossref_primary_10_3892_ijo_2024_5623
crossref_primary_10_1016_j_ejca_2020_11_014
crossref_primary_10_1016_j_ymthe_2023_01_017
crossref_primary_10_1186_s12916_021_02006_4
crossref_primary_10_1038_s41591_021_01233_9
crossref_primary_10_1158_1078_0432_CCR_21_4413
crossref_primary_10_1158_0008_5472_CAN_20_3977
crossref_primary_10_1186_s13045_019_0762_1
crossref_primary_10_1186_s12943_024_01987_z
crossref_primary_10_3390_immuno1040029
crossref_primary_10_1007_s10396_022_01201_x
crossref_primary_10_1080_2162402X_2020_1796002
crossref_primary_10_3389_fmolb_2022_743515
crossref_primary_10_1038_s41467_021_24132_6
crossref_primary_10_1080_08820139_2020_1801721
crossref_primary_10_1080_2162402X_2022_2029299
crossref_primary_10_3390_ijms25105146
crossref_primary_10_1080_2162402X_2019_1591878
crossref_primary_10_3389_fcell_2021_739161
crossref_primary_10_1016_j_critrevonc_2019_07_011
crossref_primary_10_1007_s10238_023_01227_6
crossref_primary_10_4049_jimmunol_2300038
crossref_primary_10_1002_anie_202006117
crossref_primary_10_1073_pnas_2417529122
crossref_primary_10_1002_iid3_70126
crossref_primary_10_1038_s41598_024_62913_3
crossref_primary_10_1002_adhm_201801320
crossref_primary_10_3389_fonc_2022_1035884
crossref_primary_10_1016_j_ygyno_2020_06_499
crossref_primary_10_1038_s41467_024_54081_9
crossref_primary_10_1002_cdt3_18
crossref_primary_10_3389_fimmu_2021_619209
crossref_primary_10_1002_adhm_202401076
crossref_primary_10_3389_fmolb_2022_849363
crossref_primary_10_1001_jamanetworkopen_2025_27769
crossref_primary_10_1016_j_lungcan_2022_01_016
crossref_primary_10_1038_s41698_025_00886_w
crossref_primary_10_3390_biomedicines11020308
crossref_primary_10_1016_j_ccr_2020_213355
crossref_primary_10_1038_s41419_023_06079_2
crossref_primary_10_1016_j_intimp_2024_112233
crossref_primary_10_1038_s41467_023_40850_5
crossref_primary_10_1186_s12885_023_11042_7
crossref_primary_10_1007_s11033_024_09335_6
crossref_primary_10_1007_s00432_022_04139_2
crossref_primary_10_3389_fimmu_2022_959114
crossref_primary_10_3389_fimmu_2024_1415736
crossref_primary_10_3390_vaccines9050525
crossref_primary_10_1038_s41556_020_0562_4
crossref_primary_10_1038_s41586_021_03520_4
crossref_primary_10_1002_jmv_29568
crossref_primary_10_3390_cells11193033
crossref_primary_10_3389_fimmu_2021_744381
crossref_primary_10_1016_j_addr_2020_12_003
crossref_primary_10_3389_fimmu_2023_1189960
crossref_primary_10_3748_wjg_v30_i13_1815
crossref_primary_10_1016_j_ccell_2024_09_010
crossref_primary_10_3389_pore_2023_1611086
crossref_primary_10_3390_app12052292
crossref_primary_10_1186_s40425_019_0647_4
crossref_primary_10_3389_fimmu_2021_777524
crossref_primary_10_1038_s41571_019_0272_7
crossref_primary_10_1002_adma_202110614
crossref_primary_10_7717_peerj_16263
crossref_primary_10_1016_j_canlet_2020_10_046
crossref_primary_10_3390_cancers14030751
crossref_primary_10_1016_j_cmet_2018_11_003
crossref_primary_10_1016_j_jconrel_2022_10_047
crossref_primary_10_1016_j_trecan_2024_08_004
crossref_primary_10_1016_j_biomaterials_2022_121378
crossref_primary_10_3390_cancers16233973
crossref_primary_10_1080_2162402X_2021_1909296
crossref_primary_10_1016_j_bios_2024_116792
crossref_primary_10_1038_s41423_021_00727_3
crossref_primary_10_1038_s41423_025_01331_5
crossref_primary_10_1111_1759_7714_14445
crossref_primary_10_1186_s12943_021_01464_x
crossref_primary_10_1016_j_jhep_2019_08_026
crossref_primary_10_1177_11779322221115548
crossref_primary_10_1016_j_ymthe_2022_05_008
crossref_primary_10_1088_1361_6528_ab1770
crossref_primary_10_1136_jitc_2022_005026
crossref_primary_10_1124_jpet_121_000629
crossref_primary_10_3892_etm_2020_8423
crossref_primary_10_1016_j_cancergen_2020_12_002
crossref_primary_10_1016_j_heliyon_2024_e28600
crossref_primary_10_3390_pharmaceutics15082045
crossref_primary_10_1038_s41416_018_0353_x
crossref_primary_10_1080_2162402X_2020_1729022
crossref_primary_10_1002_adma_202310982
crossref_primary_10_1080_2162402X_2020_1760676
crossref_primary_10_1016_j_semradonc_2021_11_001
crossref_primary_10_1089_hum_2024_254
crossref_primary_10_1016_j_nantod_2023_102102
crossref_primary_10_1016_j_tips_2019_11_004
crossref_primary_10_3389_fonc_2022_864301
crossref_primary_10_1080_2162402X_2020_1794424
crossref_primary_10_1016_j_ctrv_2024_102843
crossref_primary_10_3389_fimmu_2019_02293
crossref_primary_10_1016_j_ccell_2021_11_003
crossref_primary_10_1016_j_cellimm_2020_104262
crossref_primary_10_1016_j_ebiom_2024_105503
crossref_primary_10_1073_pnas_2215732120
crossref_primary_10_15252_embj_2021108863
crossref_primary_10_1080_2162402X_2021_1889822
crossref_primary_10_1080_2162402X_2019_1571389
crossref_primary_10_1186_s13578_023_01135_y
crossref_primary_10_3389_fimmu_2022_986785
crossref_primary_10_3389_fonc_2019_00276
crossref_primary_10_1007_s00432_022_03931_4
crossref_primary_10_1016_j_semcancer_2021_08_008
crossref_primary_10_1007_s13402_021_00602_3
crossref_primary_10_1172_JCI158661
crossref_primary_10_1126_scitranslmed_adn6921
crossref_primary_10_1038_s41467_021_22308_8
crossref_primary_10_1038_s41467_021_27833_0
crossref_primary_10_2139_ssrn_3805194
crossref_primary_10_1038_s41467_021_27620_x
crossref_primary_10_1038_s41467_024_46873_w
crossref_primary_10_1039_D0NR05953F
crossref_primary_10_1016_j_apsb_2020_12_018
crossref_primary_10_1136_jitc_2021_002474
crossref_primary_10_3390_ijms232213774
crossref_primary_10_1002_cti2_1215
crossref_primary_10_1002_ijc_33415
crossref_primary_10_1007_s00262_021_02947_y
crossref_primary_10_1016_j_nantod_2022_101696
crossref_primary_10_1080_2162402X_2022_2101596
crossref_primary_10_1016_j_oor_2024_100652
crossref_primary_10_1186_s12943_021_01479_4
crossref_primary_10_1016_j_ygyno_2021_07_003
crossref_primary_10_1007_s10555_025_10273_3
crossref_primary_10_3389_fimmu_2021_644350
crossref_primary_10_1038_s41392_021_00484_9
crossref_primary_10_1016_j_colsurfb_2025_115094
crossref_primary_10_1038_s41598_024_69183_z
crossref_primary_10_3389_fgene_2023_1079035
crossref_primary_10_1016_j_tcb_2020_03_004
crossref_primary_10_1126_scitranslmed_abh1261
crossref_primary_10_3389_fimmu_2022_927474
crossref_primary_10_1016_j_omto_2023_08_013
crossref_primary_10_3389_fimmu_2021_758288
crossref_primary_10_1002_cam4_3454
crossref_primary_10_1111_bph_15096
crossref_primary_10_1016_j_mtnano_2019_100029
crossref_primary_10_3390_ijms24065208
crossref_primary_10_1080_2162402X_2021_2019896
crossref_primary_10_1158_2326_6066_CIR_21_0061
crossref_primary_10_3389_fimmu_2022_989928
crossref_primary_10_3389_fphar_2021_679602
crossref_primary_10_1007_s13577_022_00791_5
crossref_primary_10_1208_s12248_019_0350_x
crossref_primary_10_3389_fcell_2021_731380
crossref_primary_10_3389_fimmu_2021_664847
crossref_primary_10_1038_s41574_019_0161_2
crossref_primary_10_1186_s12885_022_09989_0
crossref_primary_10_3389_fimmu_2020_621757
crossref_primary_10_3390_pharmaceutics15061693
crossref_primary_10_1186_s12943_025_02358_y
crossref_primary_10_3389_fimmu_2021_714822
crossref_primary_10_3389_fimmu_2022_999849
crossref_primary_10_1007_s11060_021_03907_3
crossref_primary_10_3389_fbioe_2020_00488
crossref_primary_10_1016_j_oraloncology_2021_105472
crossref_primary_10_3389_fonc_2021_651622
crossref_primary_10_1093_hmg_ddaa137
crossref_primary_10_3390_cells12020308
crossref_primary_10_1016_j_biopha_2023_115519
crossref_primary_10_3389_fimmu_2019_01776
crossref_primary_10_3389_fimmu_2023_1192506
crossref_primary_10_1016_j_canlet_2024_217079
crossref_primary_10_1080_21645515_2021_1926759
crossref_primary_10_1155_2024_5521016
crossref_primary_10_1002_adfm_202113168
crossref_primary_10_1155_2022_6575534
crossref_primary_10_3390_ijms26083506
crossref_primary_10_3389_fimmu_2023_1202169
crossref_primary_10_3389_fonc_2020_01189
crossref_primary_10_1016_j_it_2020_08_010
crossref_primary_10_3390_mi13122217
crossref_primary_10_1002_1878_0261_13317
crossref_primary_10_3389_fimmu_2022_952546
crossref_primary_10_1136_jitc_2020_001180
crossref_primary_10_1073_pnas_2208506119
ContentType Journal Article
Copyright Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Copyright_xml – notice: Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
DBID NPM
7X8
DOI 10.1126/scitranslmed.aat7807
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1946-6242
ExternalDocumentID 30232229
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA008748
GroupedDBID ---
0R~
4.4
53G
7~K
ABJNI
ACGFS
AENEX
AJGZS
AJWWR
ALMA_UNASSIGNED_HOLDINGS
BKF
C45
DU5
EBS
EJD
EMOBN
F5P
HZ~
NPM
O9-
OFXIZ
OVD
OVIDX
P2P
RHI
TEORI
7X8
ID FETCH-LOGICAL-c447t-9e33b01a4ff999305f716d8faa6d85dc95bbdd359ee7b5c74c6fe3c0c7bbd69b2
IEDL.DBID 7X8
ISICitedReferencesCount 452
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000444967400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1946-6242
IngestDate Fri Sep 05 09:24:18 EDT 2025
Thu Jan 02 23:03:27 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 459
Language English
License Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c447t-9e33b01a4ff999305f716d8faa6d85dc95bbdd359ee7b5c74c6fe3c0c7bbd69b2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0001-6718-2222
0000-0003-2257-8500
0000-0002-9265-0283
0000-0002-9334-4405
OpenAccessLink http://hdl.handle.net/10651/49975
PMID 30232229
PQID 2138633970
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2138633970
pubmed_primary_30232229
PublicationCentury 2000
PublicationDate 2018-09-19
20180919
PublicationDateYYYYMMDD 2018-09-19
PublicationDate_xml – month: 09
  year: 2018
  text: 2018-09-19
  day: 19
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Science translational medicine
PublicationTitleAlternate Sci Transl Med
PublicationYear 2018
SSID ssj0068356
Score 2.6757329
SecondaryResourceType review_article
Snippet Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
Title The hallmarks of successful anticancer immunotherapy
URI https://www.ncbi.nlm.nih.gov/pubmed/30232229
https://www.proquest.com/docview/2138633970
Volume 10
WOSCitedRecordID wos000444967400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7Uinjx_agvInhdTbrZ3exJRCxeWnpQ6K1s9gFFTWqTCv57Z5OtngTByx4CCWEyO_PNzH75AK5ig0UHU4ZI4Vs3mVQk40wRzh2ziBBMwluxCTEcZuOxHIWGWxWOVS5jYhOoTal9j_yml9CMU8ye8e3snXjVKD9dDRIaq9ChCGW8V4vx9xSBI7po2EUy5cTzIAJ1LpBmap8MXjHnXCtViywWv4PMJtn0t__7mjuwFWBmdNf6xS6s2GIPNgZhkL4PKbpH5HVU3tT8pYpKF1WLRjrRLV4jNLYPjtrOo6mnjwSS1ucBPPcfnu4fSRBQIDpNRU2kpTSPE5U6hzgQd7bD6shkTilcmdGS5bkxlElrRc60SDV3lupYC7zOZd47hLWiLOwxRJjGmObMZLZnU6rwmdRR46sRI2KjbRcul_aYoIP6qYMqbLmoJj8W6cJRa9TJrP2TxsQrFnlB8ZM_3H0KmwhWmrMaiTyDjsPtac9hXX_U02p-0Xx5XIejwRcd8LpE
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+hallmarks+of+successful+anticancer+immunotherapy&rft.jtitle=Science+translational+medicine&rft.au=Galluzzi%2C+Lorenzo&rft.au=Chan%2C+Timothy+A&rft.au=Kroemer%2C+Guido&rft.au=Wolchok%2C+Jedd+D&rft.date=2018-09-19&rft.issn=1946-6242&rft.eissn=1946-6242&rft.volume=10&rft.issue=459&rft_id=info:doi/10.1126%2Fscitranslmed.aat7807&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1946-6242&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1946-6242&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1946-6242&client=summon